Quest PharmaTech Inc. (QPT.V)
| Previous Close | 0.0200 |
| Open | 0.0250 |
| Bid | 0.0250 x 0 |
| Ask | 0.0300 x 0 |
| Day's Range | 0.0250 - 0.0250 |
| 52 Week Range | 0.0200 - 0.1000 |
| Volume | |
| Avg. Volume | 12,095 |
| Market Cap | 4.228M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | Jun 27, 2024 - Jul 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jul 21, 2005 |
| 1y Target Est | N/A |
CNW GroupQuest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director
Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced today that it has restated and refiled its January 31, 2023 annual audited financial statements and its interim unaudited financial statements for the three months ended April 30, 2023, six months ended July 31, 2023 and nine months ended October 31, 2023 each with relevant compar
CNW GroupQuest Receives Cash Dividend Payment from OncoQuest
Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced that it has received a cash dividend payment from OncoQuest Inc. ("OncoQuest", one of Quest's investee companies) of approximately Cdn $685,000. Quest has a 42.5% ownership interest in OncoQuest. The dividend income will be used by Quest for general corporate purposes.
CNW GroupOregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits
Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced that it has received information that the Phase III clinical trial of oregovomab for the treatment of Ovarian Cancer, sponsored by CanariaBio Inc ("CAB"), has received recommendations from the Data Safety Monitoring Board (DSMB), an independent committee appointed by CAB to advise
